Zealand Pharma A/S (CPH: ZEAL)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 50.87B |
| Revenue (ttm) | 76.87M |
| Net Income (ttm) | -1.05B |
| Shares Out | 70.65M |
| EPS (ttm) | -16.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,652 |
| Open | 710.00 |
| Previous Close | 728.00 |
| Day's Range | 697.50 - 757.00 |
| 52-Week Range | 342.20 - 972.00 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 20, 2025 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III... [Read more]
Financial Performance
In 2023, Zealand Pharma's revenue was 342.79 million, an increase of 229.65% compared to the previous year's 103.99 million. Losses were -703.74 million, -41.46% less than in 2022.
Financial StatementsNews
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: Z...
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
The CEO of Danish drugmaker Zealand Pharma said on Friday that data posted by Novo Nordisk's late-stage study of its next-generation obesity drug CagriSema supported Zealand's own monotherapy approach...
FDA drug rejection hits Zealand Pharma shares
Treatment for short bowel syndrome fails to win approval from US regulator
FDA rejects Zealand Pharma's drug for short bowel syndrome
US FDA declines to approve Zealand Pharma's bowel disease drug
The U.S. Food and Drug Administration declined to approve Zealand Pharma's bowel disease drug, the company said on Thursday.
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concl...
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
Zealand Pharma A/S 2024 Q3 - Results - Earnings Call Presentation
Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide
Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its obesity treatment candidate petrelintide.
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the fir...
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
Zealand Pharma to participate in the Jefferies London Healthcare Conference
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
Zealand Pharma Gains as JPMorgan Flags $10 Billion Opportunity
Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, after analysts at JPMorgan Chase & Co. predicted the Danish biotech firm’s...
Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4
Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.
Zealand’s Weight-Loss Drug Has Minimal Side Effects in Study
Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than some other next-generation contenders in the growing market for obesity dr...
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/...
Zealand Pharma seeks partner for its 'next generation' weight loss drug
CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.
Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.
Can this European biotech challenge Eli Lilly in the booming weight-loss market?
GLP-1s have dominated discussions in 2024 among those exploring weight-loss treatments. However, Zealand Pharma A/S (CPH: ZEAL), a Danish biotechnology firm, is already developing what it calls the “n...
Zealand Pharma seeks partner for its 'next generation' weight loss drug
CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.
Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.
Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly. CEO Adam Steensberg herald...
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Lette...